SCHEMBL29759805

SCHEMBL29759805

Cc1ncc(NC(=O)CN2CCC3(CC3)C2)cc1NC(=O)c1cnn2cc(-c3cnn4c3COCC4)sc12

nearest known ligand 0.32

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ WNT3A P56704 1/20 0.32
▸ CCNT1 O60563 1/20 0.32
▸ CDK9 P50750 1/20 0.32
▸ IRAK4 Q9NWZ3 4/20 0.31
▸ POLQ O75417 1/20 0.31
▸ RAF1 P04049 2/20 0.30
▸ BRAF P15056 2/20 0.30
▸ OGA O60502 2/20 0.30
▸ WNT1 P04628 2/20 0.30
▸ GSK3B P49841 2/20 0.30
▸ DYRK1A Q13627 2/20 0.30
▸ JAK2 O60674 1/20 0.30
▸ JAK1 P23458 1/20 0.30
▸ KCNH2 Q12809 1/20 0.30
▸ HDAC1 Q13547 1/20 0.30
▸ DRD3 P35462 1/20 0.30
▸ TMEM97 Q5BJF2 1/20 0.30
▸ SIGMAR1 Q99720 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24577950 1.00 WNT3A (0.32) WNT3ACCNT1CDK9IRAK4POLQ
SCHEMBL24577467 0.91 IRAK4 (0.33) WNT3ACCNT1CDK9IRAK4POLQ
SCHEMBL29759586 0.91 IRAK4 (0.33) WNT3ACCNT1CDK9IRAK4POLQ
SCHEMBL24577464 0.91 WNT3A (0.34) WNT3ACCNT1CDK9IRAK4POLQ
SCHEMBL24578250 0.91 WNT3A (0.34) WNT3ACCNT1CDK9IRAK4POLQ
SCHEMBL29759708 0.87 CCNT1 (0.35) CCNT1CDK9IRAK4POLQRAF1
SCHEMBL24579079 0.87 CCNT1 (0.35) CCNT1CDK9IRAK4POLQRAF1
SCHEMBL24579093 0.87 CCNT1 (0.33) CCNT1CDK9IRAK4RAF1BRAF
SCHEMBL24577425 0.87 CHRM1 (0.40) CCNT1CDK9IRAK4RAF1BRAF
SCHEMBL29759504 0.87 CHRM1 (0.40) CCNT1CDK9IRAK4RAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 — — US disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 WNT3A 2910/4885CCNT1 1550/4885CDK9 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback